Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
rare disease
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
27 mars 2025 16h05 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Pleco Therapeutics Announces Positive Outcome of Pre-IND meeting with FDA for PTX-252 in Acute Myeloid Leukaemia
26 mars 2025 03h00 HE
|
Pleco Therapeutics B.V.
Pleco Therapeutics announces positive FDA feedback on PTX-252, supporting IND pathway for its novel AML treatment.
Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting
21 mars 2025 16h30 HE
|
Baylor Genetics
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory celebrating a decade at the forefront of genetic testing, today shared research on the value of both...
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
20 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
20 mars 2025 02h00 HE
|
Pharming Group N.V.
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients...
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
19 mars 2025 07h30 HE
|
Plus Therapeutics Inc.
Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
17 mars 2025 07h01 HE
|
Travere Therapeutics, Inc.
Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition.
Baylor Genetics to Showcase Genetic Testing Innovations for Rare Disease at ACMG 2025 Annual Clinical Genetics Meeting
11 mars 2025 10h00 HE
|
Baylor Genetics
HOUSTON, March 11, 2025 (GLOBE NEWSWIRE) -- As Baylor Genetics celebrates a decade of leadership at the forefront of genetic testing, it is set to exhibit its latest scientific studies in genetic...
Zollinger Ellison Syndrome Market Research 2025: Novartis, GSK Plc, Bayer, Pfizer., and Bristol Myers Squibb Leading the $1.34 Billion Landscape - Forecasts to 2034
07 mars 2025 11h41 HE
|
Research and Markets
Dublin, March 07, 2025 (GLOBE NEWSWIRE) -- The "Zollinger Ellison Syndrome Market" report has been added to ResearchAndMarkets.com's offering.The Zollinger Ellison Syndrome market was valued at USD...
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
04 mars 2025 14h06 HE
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds